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Despite its classification as a psychiatric disease, schizophrenia is both a behavioral and a biological 
disorder resulting in neurocognitive dysfunction. Social and economic costs of schizophrenia are 
extremely high compared to its incidence and prevalence, however, due to a heterogeneous pattern 
of brain pathology and symptoms and to an unknown etiology, developing an effective treatment has 
been really challenging. Among the many neurochemical hypothesis, the dysregulation of 
dopaminergic neurotransmission has been considered as a central dogma of schizophrenia over the 
last few decades. In fact, patients with this pathology exhibit increased dopamine (DA) synthesis and 
release in the striatum which seems to correlate with positive symptoms and moreover, most of the 
effective antipsychotic drugs (APDs) are D2-receptor antagonists. Unfortunately, chronic treatment 
with APDs is associated with the induction of extrapyramidal side effects (EPS). In order to identify 
new possible APDs with a novel mechanism of action and potentially less EPS we tested 3 different 
compounds generated from the structural modification of vanoxerine (or GBR12909), a known 
atypical inhibitor of the presynaptic DA transporter (DAT) with cocaine-like activity but cardiotoxic 
properties that have precluded its clinical use. Preliminary in vitro studies showed that DAhLIs (DAT 
atypical inhibitors) are able to bind to DAT and inhibit DA reuptake. Additionally, our in vivo results 
showed that DAhLI i) have putative central effects, ii), unlike vanoxerine, reduce novelty-induced 
locomotor activity, and iii) counteract cocaine stimulating effects, suggesting that DAhLI may 
potentiate DA reuptake via DAT. These compounds may provide a way to reduce DA extracellular 
levels and DA neurotransmission with a selective action on active DA synapses, thus with reduced EPS 
typical of D2 antagonists, representing a new promising class of presynaptic APDs. 
 
 
 
